CYP19A1 and breast cancer: Testing of women with non-metastatic breast cancer to predict those who will not respond to tamoxifen therapy could inform decisions regarding choice of alternative treatment strategies including chemotherapy or the use of aromatase inhibitors (for post-menopausal women in particular [1].